Ironwood Pharmaceuticals (IRWD) to Release Earnings on Thursday

Ironwood Pharmaceuticals (NASDAQ:IRWD - Get Free Report) is scheduled to announce its earnings results before the market opens on Thursday, May 9th. Analysts expect the company to announce earnings of $0.19 per share for the quarter. Investors interested in participating in the company's conference call can do so using this link.

Ironwood Pharmaceuticals Price Performance

Shares of IRWD stock traded up $0.08 during trading hours on Thursday, reaching $8.30. The stock had a trading volume of 1,598,247 shares, compared to its average volume of 4,278,514. The stock's fifty day simple moving average is $9.09 and its 200 day simple moving average is $10.63. Ironwood Pharmaceuticals has a 12 month low of $7.53 and a 12 month high of $15.70.

Insider Buying and Selling at Ironwood Pharmaceuticals

In other Ironwood Pharmaceuticals news, insider Minardo John sold 47,380 shares of Ironwood Pharmaceuticals stock in a transaction that occurred on Monday, February 12th. The shares were sold at an average price of $15.24, for a total transaction of $722,071.20. Following the completion of the sale, the insider now directly owns 224,796 shares in the company, valued at $3,425,891.04. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. In other news, insider Minardo John sold 47,380 shares of the business's stock in a transaction that occurred on Monday, February 12th. The shares were sold at an average price of $15.24, for a total value of $722,071.20. Following the completion of the sale, the insider now directly owns 224,796 shares in the company, valued at approximately $3,425,891.04. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, SVP Andrew Davis sold 9,846 shares of the business's stock in a transaction that occurred on Monday, February 12th. The stock was sold at an average price of $15.24, for a total transaction of $150,053.04. Following the completion of the sale, the senior vice president now owns 208,324 shares of the company's stock, valued at $3,174,857.76. The disclosure for this sale can be found here. Insiders sold a total of 273,008 shares of company stock worth $4,160,642 over the last three months. 13.10% of the stock is owned by insiders.

Analysts Set New Price Targets

A number of equities analysts have recently commented on IRWD shares. Craig Hallum started coverage on shares of Ironwood Pharmaceuticals in a research report on Wednesday, January 17th. They issued a "buy" rating and a $21.00 price objective for the company. Wells Fargo & Company cut their price objective on shares of Ironwood Pharmaceuticals from $20.00 to $14.00 and set an "overweight" rating for the company in a research report on Friday, March 1st. Piper Sandler lifted their target price on shares of Ironwood Pharmaceuticals from $20.00 to $21.00 and gave the company an "overweight" rating in a research report on Friday, February 16th. Finally, StockNews.com lowered shares of Ironwood Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Saturday, April 6th. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat.com, Ironwood Pharmaceuticals currently has an average rating of "Moderate Buy" and an average price target of $19.80.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.